bioAffinity Completes $4 Million Registered Direct Offering

Jersey City, N.J. – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) priced a registered direct financing of common stock at about $4 million. The transaction also included a private placement that was sold at-the-market under Nasdaq rules. WallachBeth Capital LLC acted as the placement agent. The company set the share price at $6.122. The private placement added warrants that allow the purchase of up to 980,072 additional shares. The closing is expected around October 9, 2026, subject to standard conditions.

Structure and Pricing

The direct financing was a sale of common stock to institutional investors. Gross proceeds are estimated at roughly $4 million before fees and expenses. This approach lets the company raise capital without a full underwriting process. The private placement includes warrants that can be exercised for the additional shares. The dual structure is common in at-the-market offerings and gives flexibility to both the issuer and investors. WallachBeth Capital LLC managed the placement. The firm works with smaller and mid-cap companies to connect them with institutional capital through structured offerings.

Biotech Financing Landscape

Registered direct offerings are a frequent tool for biotechnology firms that need quick access to cash. They usually close faster and cost less than traditional public offerings. For bioAffinity, timely funding supports product development and operational milestones.

Market research from Capital Markets Market projects the broader capital-markets industry to reach $985.2 billion by 2034, growing at a 6.8% CAGR from a 2025 base of $545.0 billion. The growth reflects rising demand for fast, flexible financing structures across sectors, including biotech.

The at-the-market pricing used in this deal set the share price based on current market conditions. This method helps avoid large price swings for existing shareholders compared with a block sale.

Use of Proceeds

The $4 million in gross proceeds will fund bioAffinity’s ongoing operations and development work. The capital can be directed toward clinical studies, regulatory filings, or preparation for commercial launch, depending on the company’s needs. The warrants give the company a possible future source of cash if the stock price rises above the exercise price. While this can provide additional funding, it may also dilute existing shareholders if the warrants are exercised. Investors will watch how bioAffinity allocates the funds and whether the company announces new milestones or partnerships in the coming months. The financing step is a routine but important part of the company’s capital plan, helping bridge to the next phase of development.

Readers can explore more corporate financing news in the Press Release Archives for additional analysis.